WHO Resolution Signals a Global Commitment to Precision Medicine Equity
Last week at the 79th World Health Assembly, Member States advanced a landmark resolution recognizing precision medicine as an important component of the future of global healthcare. For the colorectal cancer community, this marks an important moment in the growing international recognition that access to biomarker testing, molecular diagnostics, and targeted treatments cannot remain limited to a small number of countries or healthcare systems.
The resolution acknowledges the rapid evolution of genomics, molecular diagnostics, and data-driven healthcare, while emphasizing that these advances must be implemented ethically and equitably across all regions. It also highlights the need for stronger infrastructure, workforce development, data systems, and governance frameworks to support precision medicine, particularly in low- and middle-income countries.
For the Global Colon Cancer Association, the resolution reflects priorities that patient advocates around the world have been raising for years. Precision medicine has already transformed colorectal cancer care in many settings through biomarker testing and targeted therapies that can help guide treatment decisions and improve outcomes. Yet access remains deeply unequal.
In many countries, patients still face barriers to timely biomarker testing, limited availability of molecular diagnostics, workforce shortages to support that testing, and insufficient awareness among both healthcare professionals and the public. These gaps can delay diagnosis, restrict treatment options, and widen existing health inequities.
Importantly, the resolution also recognizes the role of patient engagement, health literacy, and public trust in the successful implementation of precision medicine. Ensuring that patients and communities understand biomarker testing and personalized treatment approaches is essential to making these advances meaningful in real-world care.
Nicole Sheahan, President of the Global Colon Cancer Association, welcomed the resolution as an encouraging step toward more equitable cancer care worldwide. “GCCA is deeply encouraged to see precision medicine recognized as a global health priority at the WHO level. For colorectal cancer patients, access to biomarker testing and targeted treatments can shape care decisions and open the door to more personalized approaches. This resolution acknowledges that innovation alone is not enough. Countries also need the infrastructure, workforce, education, and policies necessary to ensure these advances reach patients everywhere, not only in high resource settings.”
The resolution further calls on countries to strengthen laboratory and diagnostic capacity, invest in genomics and digital health infrastructure, expand training in genomics and bioinformatics, and promote equitable participation in research and data systems. It also requests that WHO consider developing a global strategy on precision medicine, with additional reporting expected in the coming years.
For GCCA and the global colorectal cancer advocacy community, this momentum represents an important opportunity to continue advancing awareness, education, and equitable access to biomarker testing and precision oncology worldwide.
As implementation discussions move forward, patient organizations will remain essential partners in ensuring that precision medicine policies are grounded in the real experiences and needs of people affected by colorectal cancer.